Skip to main content
. 2024 Jan 4;31(4):2727–2736. doi: 10.1245/s10434-023-14834-0

Table 2.

Operative characteristics and perioperative outcomes in patients according to method of pelvic lymph node surgery (open or robot-assisted approach)

oPLND (n = 8)
(2012–2016)
rPLND (n = 14)
(2017–2023)
pa
Extent of surgery 0.665
 PLND alone (no inguinal LND) 37.5 (n = 3) 28.6 (n = 4)
 Inguinal LND + PLND 62.5 (n = 5) 71.4 (n = 10)
Total operative time, min 0.335b
 Median (IQR) 174 (158–216) 250 (160–303)
Total pelvic dissection time, min 0.836b
 Median (IQR) 130 (95.5–182) 126 (97.8–161)
Total groin dissection time, min* 0.036b
 Median (IQR) 72 (69.5–103) 112 (83–117)
Length of inpatient stay, days 0.006b
 Median (IQR) 5.34 (3.77–6.94) 1.98 (1.39–3.50)
Complications, Clavien-Dindo score 0.699c
 0 12.5 (n = 1) 7.1 (n = 1)
 I 12.5 (n = 1) 35.7 (n = 5)
 II 50.0 (n = 4) 50.0 (n = 7)
 IIIa 25.0 (n = 2) 7.1 (n = 1)
No. pelvic lymph nodes identified on pathology 0.629b
 Median (IQR) 6.5 (6.0–12.5) 6.0 (3.75–9.0)
No. positive pelvic nodes 0.729b
 Median (IQR) 1.5 (1.0–3.8) 2.0 (1.0–3.0)
Distribution of positive pelvic nodes 0.667c
 0 12.5 (n = 1) 7.1 (n = 1)
 1 37.5 (n = 3) 35.7 (n = 5)
 > 1 50.0 (n = 4) 57.1 (n = 8)
Total positive regional lymph nodes (pelvic + inguinal) 0.821b
 Median (IQR) 2.5 (1.25–3.75) 3.0 (1.0–7.0)
Largest metastatic focus (mm) 0.623b
 Median (IQR) 45.0 (25.0–72.0) 30.0 (19.8–65.0)
 Missing 0 3
Extracapsular spread 0.965
 Present 37.5 (n = 3) 38.5 (n = 5)
 Absent 62.5 (n = 5) 61.5 (n = 8)
 Missing 0 1
Time to adjuvant therapy, weeks 0.018b
 Median (IQR) 11.6 (10.6–18.5) 7.71 (6.29–10.4)

Values are percentages unless otherwise indicated. *Includes five patients in the oPLND group and ten patients in the rPLND group. Excludes two hospital stays of 41 days and 21 days in rPLND group due to nonsurgical factors detailed in Results. aχ2 test; bunpaired t test; cχ2 for trend test